Nymox Pharmaceutical Corp (NYMX)

NASDAQ
1.8900
-0.2000(-9.57%)
After Hours
2.1000
+0.2100(+11.1111%)
- Real-time Data
  • Volume:
    268,930
  • Bid/Ask:
    1.9500/2.1000
  • Day's Range:
    1.8900 - 2.0600

NYMX Overview

Prev. Close
2.09
Day's Range
1.89-2.06
Revenue
-
Open
2.06
52 wk Range
1.26-3.49
EPS
-0.16
Volume
268,930
Market Cap
158.25M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
333,301
P/E Ratio
-
Beta
1.55
1-Year Change
-15.04%
Shares Outstanding
83,731,000
Next Earnings Date
Nov 10, 2021
What is your sentiment on Nymox Pharmaceutical Corp?
or
Market is currently closed. Voting is open during market hours.

Nymox Pharmaceutical Corp News

Nymox Pharmaceutical Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Nymox Pharmaceutical Corp Company Profile

Nymox Pharmaceutical Corp Company Profile

Employees
3

Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Read More
  • It will be double
    0
    • This stock has a superior Risk/return - approaching a decision on a new drug in a huge market (enlarged prostate and prostate cancer).  HEAVY Insider buying and positive indications toward an approval in a European Decentralized Approval process.  Will send the stock up 3 fold minimum.  A disapproval will send it down 3 points.  Buy it.
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.